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M6~““n~oli.s. Mirazrr,>,a 
growth in knowledge regarding the modulation of “sympa. 
thetk traflV’ to neurwtTector or~ns, including vascular 
t&c. The release of noreQineQhr& from peripheral sym 
pathetic neu~ll~ is nuw known to be under both negative 
and wsitive feedback eontrot. Nareoineohrine. when IE. 
lea&t from peripheral neunms, acts .,I Q&mptiealQha,. 
receptors to inhibit further nour(ltransmission. Varwtnr 
postsynaptic alpha,receptors, sensitive to cirrutating ate- 
cbalsminas, subwve vaswonstrieticm. The antihyperten- 
sive agents clonidine, guanabenr and guanfarin likely rr- 
duce blood pressure by acting rentrstt> on alpha, 
postsynaptie neurons to limit sympathetic LpBnsmission to 
blood vessels. Clonidine can prodwe venwastrietion and 
tberehv imwwe ~rtbwtatie hv.o,e”~to” b” ~ctivMine ve. 
now aiph&r~ptors. Addilk& presyn&c dopan& 
gic receptors (DAI), museari*ic reeeplors (acetytehhotine), 
opioid reeeptars, proataghndin reeeQtors, adoomine recep- 
tors (A,) and histamine (Hd reeeplors are present on 
sympathetic wrve membranea end, when ewaged with the 
appropriate liiand, ran timil the oxwytotic prows. Cam. 
ma.aminobutytic acid and arotonin demonstrate sbnllar 
roles in reducing sympathetic nerve activfty. In contrwt to 
these inhibitory presynaptic meehardsms, f.xItltatkm of 
noreQtneQhri”e releasenppearstow~ur by wayofneuranal 
angiotensin U rewptor aettvation and perhaps through 
stimulation of sympathetic nerve membrane beta,- 
receptors. An appreciation of these inhibitory and Iadtita- 
tar mtianisms 1s useful in the tnstment of a variety of 
rlinicsl conditions, including hyportenskm. heart failure, 
orlhostatic hyptension, septic shock and a number ol 
common withdrawal syndromes. 
The past 15 years have witnessed remarkable progress in 
adrenergic receptor research. Knowledge of this area has 
been largely the domain of basic pharmacologists, but with 
the introduction of new therapies designed to modulate 
ncurotldnsmission between sympathetic neurons and vascu- 
lar as well as myocardial tissue. there ia an important need 
for cimicians to more critically assets these advances. This 
brief review will attempt to focus on our current understand- 
ing of those factors that modulate the release of norepinegh. 
rine from the terminal sympathetic neurons. Two p&s& 
imponant when considering this material: I) most of the 
experiments have been dune in isolated preparations or in 
small aoimals, or both, rather than in humans, and 2) there is 
great heterogeneity throughout various organ systems. Qar- 
titularly the vascular system, in the anatomic size of the 
neuroeffector junction and the density of adrenergic inner- 
vation. 
Synthesis, Storage and Release of 
Norepinephrine 
Synthesis. It has long been known that adrenergic nerve 
endings arc involved in the synthesis. storage, release and 
inactivation of norepinephrine. Norepinephrine is synthe- 
sized larwlv in Ibe cell badv of the nerve and also durinc 
transporild the distal neuron varicosilies where it is storei 
in large (75 to 90 nm) and small (45 to 55 nm) vesicles (I). 
This transport process is believed to take several days and 
OCCUR through the microtubule transport system. An aver- 
age adrenergic neuron gives rise to approximately IO cm of 
terminal axon. which typically has about 25,wO varicosities. 
In vascular tissue, the distance between varicosity and the 
smooth muscle cell varies from 50 nm or 100 A in small 
arterioles up to 20,000 .i in large vessels. Whereas the 
nerves do not penetrate beyond the adventitial medial layer 
in most arteries, they do penetrate into the muscular media 
in most veins. 
I _ 
storage function. and their c&titoents induds n&pinsph- n&zp&eph&e is unclear. but it is posrible that activation of 
tine. synthetic proteins. adenoaine triphosphatase (ATPaael. thev rrcsptorr reduces the availability of c&urn for exci- 
chromogranin A. opioid peptides. dopamine beta hydrory- tation~secretion. Calcium entry by way of voltage-galed 
lase. synapsin I, calmodolin and neuropeptide Y. The sn all Ca’ ’ Is essentiai fol oeuotransmitie~ re&z.; C%. T0e ma:- 
vesicles conmitt primardy norepincphrine (roughly 900 mol- nwdc III reduction of norepinephrine release by way of 
ecules per vesicle). and probably do not synthesize norcpi- alphal-receptor stimulation is more pronounced in low fre- 
nephrioe. but mainly serve both a storage and a r&ax quency ncrvc stimulation (9). although this is somewhat 
mechanism. In humans. about 70% of the vc\iclc\ arc of tbc ~ontro~ers~d (10L However. the concept of presynaptic 
small variety. alpha.-receptors being more responsive to low frequency 
Release. A single nerve impulrc empties only a sm&li 6nulalion is consibttent with the current opinion that these 
fraction ofthe narepinephrine content of a vesicle. probably receptors are tine modulators of sympathetic activity rather 
releasing about 369 to 400 molecules per varicos!ty (2). It IS thdn potent negative feedback inhibitors of markedly in- 
still uncertain if each impulse actiwtes only a few wicosi- creahed sympathetic drive. 
ties at a time or if a volley of 5 to IU impu!se\ are needed to C’omnw~rl~ ssrd alpho,-rerupror oponi.m are clonidine. 
activate a Single varicosity. There is debate as to whether poanabcnr and goanfacin, all of which are clinically w&Me 
each quantum of norepinepbrine released is the partial antibypcrtcnrivc agents. Although these agents act primarily 
contents of a single vesicle or the partial content of xverdl in the centr.11 newoos syrtcm (probabl) on postsynaptic 
vesicles. The contents of the large veicles are released alpha:-receptorsl. they are also known to activate peripheral 
during very marked sympathetic activity and have roughly sympathetic presynaptic alpha?-receptors to reduce norepi- 
IO times more norepinephrine content. nephrine erocytosis II I-13). When injected intn-arterially. 
Uptake. In the 1960s it became clear that as much a 80% clonidine produces vasoconstriction. presumably because of 
of th’e liberated norepinephrine is taken back into adjacent 
nerve ending by on active transport mechanism (uptake It 
(3). Other amines structurally related to norepinephrine are 
also taken up by this process. but the affintty for norepineph- 
rine is far greater. Norepinephrine is taken up through the 
axon membrane, often into a storage gwule where it can be 
released again. In large vessels. where synaptic cleft wid!h is 
large, much of the norepinephrine diffuses away. In smaller 
vessels, reaction time is faster and neuronal reuptake is more 
important. Uptake I can be blocked by cocaine. ampheta- 
mines and some tricyclic antidepressant drugs. Only a very 
small amount of the norepinephrine released is actually 
available to activate effector orgnn receptors or to enter 
smooth or cardiac muscle directly (uptake 21. Only a fraction 
of norepinephrine enters the circulation where it can be 
measured by radioenzymatic or high pre~ore liquid chm- 
matography techniques. 
Sympathetic Nerve Receptors 
Pawnantic aloha, receoton. It has been oostulated that . 1 
the p&m&ional sympath’etic neuronal membrane contains 
receptors that “sense” the concentration of norepinephnne 
in the junctional cleft (4.5). Many phamtacalogic studies 
have suggested the existence of an alphandrenergic receptor 
population on prejunctional peripherd rympathetic nerve 
membrdnes which, when activated by norepinephrine in IL 
junctional synaptic cleft, inhibit the further releax of nor- 
epinephtine. thereby exerting negative feedback on the 
exocytotic process (6.7). These receptors are of the alpha, 
variety (6) and have been reported to be present in all of the 
peripheral tissues explored to date. The mechanism of how 
portjunctieozz or vascular alpha,-receptor stimulation. Yo- 
himbine is a relatively ,ekctive presynaptic alpha,-blocking 
agent that increases transmitter overflow. resulting in in- 
creased plama norepinephrinr levels ii4L 
Pres~naptic dopamine receptors. Presywptic dopamine 
receptors (referred to BS DA, recepton) subserve inhibition 
of nolcpinephrine release and are present on both the centradl 
and peripheral sympathetic nerves. Postsynaptic dopamine 
receotors Ireferred to as DA, receptors) are evident in 
w&r beds (renal, mesenteric. cerebral and cumnary) and 
sobscwe varodilation. Bmmocriptine is a DA, agonist. It is 
known to reduce circulating norcpinephtine by as much as 
5099 t ISI. The oresvnaotic inhibiton effects of DA, wonists . 
on oo;adrene& tnnsmisrion are more pronoonc~dat low 
freqoencne< of stimulation. but can reduce plasma norepi- 
nephrme in states of increased plasma norepinephrine. such 
a congestive heart failure flhj. DA, receptors can be 
blocked by metoclopmmide, which can pote&ally lead to 
heightened sympathetic activity by inhibiting the normally 
operative DA, negative feedback loop. Metoclopramide has 
been noted to induce dangerous increases in blood pressure 
in patients with pheochr&ocytama (171. 
Presynaptic muxatinic receptors. Presynaptic inhibitory 
muswinic receotor~ ale evident in the membranes of pe- 
lipheral adrene&ic nerve endings and subserve reduction in 
noreoineohrinerelesse, probably by reducingtheavailability 
of calcium for excitatidn-r&ion coupling (IS). ERerent 
stimulation of the vagos nerve releases acetylcboline, which 
then presumably acts an adjacent sympathetic nerve mosc~- 
rink receptors to reduce the output of norepinephrine. It 
appears that these piesynaptic inhibitory muscarinic recep 
ton are identical with the postsynaptic muscarinic receptors 
in the heart. and tbcv can be blocked bv atropinc. There may mechanisms is not clear. They may have a primary role in 
also be alpha, pre&naptic receptor; on &rasympathetic 
nerve endings that subserve en inhibition of acetylcholine 
release (19). addmg further complexity to the interaction of 
tb* sympathetic and parasympathetic systems at the neu- 
roetiectorjunction. 
Presynaptie opioid receptors. Noradrenergic oeurotrans- 
mission i, inhibited in the peripheral sympathetic nervous 
‘jystcm by opiates (6). but this activity seems re%ricted to 
only a few neuroeffcctor organs (6). The naturally occurring 
penta peptides are far more potent than is morphine in this 
regard (201. The enkephalins also reduce norepinephrine 
release, and this can be blocked by naloxme. Blocking the 
presynaptic opiate receptor likely increases synaptic cleft 
norepinephrine concentration and may account for some of 
the positive inotropic effects attributed to drugs such as 
nalmafene (21). 
Presynaptie prostagiandin receptors. Prostaglandins of 
the E series can inhibit the release of norepinephrine in 
certain noradrenergically innervated vascular tissues (71. 
The physie!ogic role of endogenously released prostaglan- 
dins in modulating norepinephrine release is not very clew. 
This inhibitory mechanism is independent of the inhibition of 
oorepinephrine release modulated by presynaptic alpha,- 
receptors. 
Presynaptic adenasine receptors. Adenosine and adenine 
nucleotides also inhibit peripheral noradrenergic neurotrans- 
mission (22.23). This activity on the presynaptic adenosine 
subtype receptor (referred to as A, receptor) likely accotmts 
for the utility ofadenosine in slowing AV node transmis+n 
in supmventricular arrhythmias (24). Nerve traffic is well 
known to be accompanied by the release of purines, includ- 
ing adenosine and its catabalites, inosine and hypoxanthine. 
It is quite possible that the endogenous release ofadenosine 
plays a physiologic role in inhibiting further release of 
norepinephrine from the nerve ending. Such a mechanism 
has been suggested to promote a protective effect in early 
myacsrdial ischemia (25). 
‘f/w rcdemainr nsngonisl rhrophglliae likely mediates 
some of its effects by competitive interference with the 
Presynaptic A, receptor, thereby further driving the svmw- 
thetic ncrvw~ syst& and secondarily inc&ing c%lar 
cyclic ndenosine monophosphate i26). Inhibition of ohos- 
phodiesterase activity by theopbyii~ne also serves to in- 
crease cellular cyclic adenosine monophosphate. 
Other presynaptie inhibitory weeptots. Histamine can 
cause prejunctional inhibition of adrcnergic neurotmnsmis- 
sion, probably by activating histamine (&I receptors on the 
tteuron;il cell membrane (271. J-hydronytryptamine (sew 
tonin) can also inhibit norepinephrine release (27). particu- 
larly at low frequencies of stimulation. Gamma-amino- 
butyric acid can also act to inhibit sympathetic 
oeurotransmissioo. The physiologic importaxe of these 
the modulation of central sympathetic net& transmission. 
Presynaptic angiotensin II receptors. In addition to the 
multipwz presynaptic inhibitory receptors present on periph- 
eral sympaihetic nerve membranes, there appear to be at 
least two important presynaptic facilitator receptors. The 
angiotensin I1 receptor, in addition to being present on 
arterioles where it subserves vasoconstriction. is also evi- 
dent on presynaptic nerve membrane where it enhances 
release of norepinephrine 128). In fact, a substantial propor- 
tion of the pressor activity ofangiotensin II can be attributed 
to its indirect effects on facilitating norepinephrine release 
(29). This facilitation of exocytosis along with enhancement 
of norepinephtine biosynthesis. ganglionic transmission and 
stimulation of central nervous system vasonwtor centers 
make angiotensin II an integral component of the sympa- 
thetic nervous system Circulating angiotensin II and angio- 
tensin generated locally in blood vessel walls are probably 
both important in this regard. 
Presynaplic beta reeeplors. There are prejunctional beta- 
adrenoceptors. presumably of the beta, subtype, which also 
mediate facilitation of norepinephrine release from sympa- 
thetic nerve endings 130). Epinephrine appears more potent 
than norepinephrine at this receptor. It is likely that suffi- 
cient anwonts of circulating epinephrine diffuse from the 
lumen back to the synaptic cleft to stimulate presymtptic 
bet+-receptors. This stimulation further enhances the re- 
lease of norepinephrine. which adds to vascular tone. Presy- 
naptic betarreceptor stimulation by epinephrine may. for 
example, play a role in the hypertension of pheochmmocy- 
toma. Some of the antihypertensive ffects of nonselective 
beta-blocking agents may be mediated by inhibition of the 
presynaptic beta,-facilitator receptor. 
Clinical Relevance 
Clonidiie. A more penetrating understanding of presyn- 
aptic and postsynaptic central and peripheral alpha,- 
receptor physiology has lead directly to the development of 
a whole class of imidazoline antihypertensive agents. Per- 
haps just as importantly. experience with these agents has 
helped to further probe the complexities of alpharreceptor 
pharmacology. Clonidine has DOW been used clinically to 
treat orthonatic hypotension (by way of stimulation of 
venous alpha, vascular receptors) (31). sudden alcohol with- 
drawal (321. narcotic addiction (33). cigarette craving (34). 
congestive heart failure (35) and pain elicited by a variety of 
nociceptive stimuli mcluding spinal cord injury (33). With 
the exception of orthostatic hypotension, virtur&y all of 
these clinical conditions are likely to improve by the ability 
of clonidine to reinstate ttewon inhibition. 
Cocaine. The role of cocaine in cardiovascular catastm- 
phes is now widely appreciated (36). Although the mecba- 
nism is not precisely defined. it is believed that cocaine can 
cause intense surges of sympathetic activny by blockmg 
neuronal reuptake (up:;ke I) of released norepinephnne. 
Coronary artery spasm. severe myocardial tschemia or in- 
farction. ventricular arrhythmias. cerebrovascular accidents 
and death may result. 
Opiate antapnisls in shnck (naloxone~. Septic ihock IC 
also a clinical syndrome in which knowledp of presynaptic 
receptor pharmacology may prove ureful. Cenam opiate 
agonists inhibit the release of norepinephnne and the ef- 
fector response elicited by sympathetic nerve transmissmn. 
These opioids appear to uct at prejunctional Sand x but nul 
IL receptors (37). Nalaxane. an opiate receptor antagonist. 
has been shown to reverse hypotcnsion in laboratory ani- 
mals subjected to hemorrhagic (38.39). endotoxic (40.41) and 
spinal shock (42.43). Naloxane may raise blood pressure in 
patients with septic shock (44.45). but haa not been shown to 
improve survival (46). Presumably, ~aloxone antagonize, a 
prejunctional sympathoinhibitory effect of endogenous 
opioids. thereby contributing to an increase in plasma nor- 
epinephrine and blood pressure during shock (47). 
Congestive heart failure and hypwtension. These are two 
comtnon clinical condiiions that may be charactcrizcd by 
disturbances in presynaptic receptor bhyaiology. Heart fail- 
ure is characterized by increased sympathetic activity (48). 
Increased plasma norepinephrine levels predict a poor sur- 
vival (49). It is possible that some of the excessive sympa- 
thetic activity in heart failure is being driven by enhanced 
angiotensin II stimulation of “facilitator” presynaptic recep 
tom. Short-term angiotensin-converting enzyme inhibitor 
treatment reduces plasma norepinephrine (SO) and improves 
survival in patients with advanced heart failure WI. Hyper- 
tension, in some circumstances, may be related to excessive 
epinephrine-induced presynaptic beta,-stimulation liZI, 
which could facilitate norepinephrine release. It has also 
been suggested that sodium may exert its hypenensive 
action by decreasing the state of affinity of the prejunctional 
alphu+ceptors in the central nervous system, leading to 
some loss of sympathetic inhibition and a resultant hyper- 
ndrenergic state (53). 
Conclusions 
Local peripheral adrenergic neurotransmission appears to 
be partially controlled by multiple types of presynaptic 
receptor modulation, with more known controls for inhibi- 
tion than for facilitation. The overall physiologic and phar- 
macologic effects of these mechanisms are now under care- 
ful scrutiny. but there is still much to be learned about their 
role in maintaining circulatory homeostasis. One point 
seems obvious. The control of peripheral sympathetic nerve 
transmission is extraordinarily complex. A thorough undcr- 
standing of the multiple receptor mechanisms operative in 
the modulation of peripheral sympathetic nerve transmission 
is a formidable task. New facts will likely continue to emerge 
rapldly. The clinical relevance of presynaptic receptor phar- 
macology w/I! likely be more widely appreciated as new 
drugs dc;:~ned to modulate peripheral sympathetic nerve 
lranbmission become available. 
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